Cancers & treatments·Regimen libraryLater line

Pegylated liposomal doxorubicin

Checked 2026-09-09

Platinum-resistant or partially platinum-sensitive ovarian cancer; Kaposi sarcoma

One cycle

every 28 days

28-day cycle, until progressionIntravenous

Components

Drug	Dose	Route	Days	Note
Pegylated liposomal doxorubicin Cytotoxic (liposomal anthracycline)	40 mg/m² (20 mg/m² every 2-3 weeks in Kaposi sarcoma)	IV	D1

Cycles

until progression

28-day cycle

Emetogenicity

Low (10-30%)

G-CSF

Not routine

Notes

Hand-foot syndrome and stomatitis; cardiotoxicity lower than conventional doxorubicin but cumulative dose still counts.

Used in

Ovarian cancer Kaposi sarcoma Multiple myeloma

Products

Pegylated liposomal doxorubicin

Source

Gordon, JCO 2001; NCCN Ovarian Cancer

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.